Evidence map›Paper›PMID 25887073›Full record

ReviewClinical journal of the American Society of Nephrology : CJASN2015

Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View.

Hiddo J Lambers Heerspink, Ron T Gansevoort

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 94 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 8 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07175051 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2026 to 2030Enrolled20ConditionsSickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaArmsEmpagliflozin (oral)
NCT07667517 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

TypeinterventionalSponsorFirst Affiliated Hospital of Zhejiang UniversityRan2026 to 2027Enrolled148ConditionsAlbuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney DiseasesArmsFinerenone (BAY 94-8862), Placebo
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 8 syntheses or guidelines pooled it, 170 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Trial
  10. Review
  11. Albuminuria or proteinuria in glomerular disease and CKD-which one to use?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. A Narrative Review of C3 Glomerulopathy: From Pathogenesis to Targeted Therapy.Canadian journal of kidney health and disease · 2026
    Review
  17. Review
  18. Article
  19. Article
  20. Advances in laboratory medicine · 2025
    Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hiddo J Lambers HeerspinkDepartments of Clinical Pharmacy and Pharmacology and h.j.lambers.heerspink@umcg.nl.
Ron T GansevoortNephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
University of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of elevated levels of albuminuria is associated with an increased risk of progressive renal function loss over time. This association is found in various pathophysiological conditions, including diabetic nephropathy, hypertensive nephropathy, and various primary renal diseases, but also, the general, otherwise healthy population. Emerging data report that elevated albuminuria causes tubulointerstitial damage through activation of proinflammatory mediators, which ultimately leads to a progressive decline in renal function. Nowadays, various drugs are available that decrease the rate of GFR loss in patients with kidney disease. Well known are renin-angiotensin-aldosterone system inhibitors, but there are also other drugs and interventions, like intensive glucose control, anti-inflammatory agents (pentoxifylline), or a low-protein diet. These interventions have an additional effect beyond their original target, namely lowering albuminuria. Analyses from clinical trials show that the reduction in albuminuria observed during the first months of treatment with these drugs correlates with the degree of long-term renal protection: the larger the initial reduction in albuminuria, the lower the risk of ESRD during treatment. In addition, in treated patients, residual albuminuria is again the strongest risk marker for renal disease progression. These observations combined provide a strong argument that albuminuria is an appropriate therapeutic target in patients with CKD.

Indexed as

AlbuminuriaAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBiomarkersDisease ProgressionGlomerular Filtration RateHumansKidneyKidney Failure, ChronicPredictive Value of TestsRenal Insufficiency, ChronicRisk FactorsSerum AlbuminSerum Albumin, HumanTime FactorsTreatment OutcomeALB protein, humanAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBiomarkersSerum AlbuminSerum Albumin, HumanUrological AgentsalbuminuriaCKDurinary protein

Identifiers

PMID25887073
PMCPMC4455219
OpenAlexW2034258292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.